Epilepsy Market Outlook

Thelansis’s “Epilepsy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Epilepsy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Epilepsy Overview

Epilepsy is a chronic neurological disorder defined by a predisposition to recurrent unprovoked seizures, resulting from abnormal excessive or synchronous neuronal activity arising from diverse structural, genetic, metabolic, infectious, immune, and unknown aetiologies, classified by the ILAE framework into focal, generalised, combined, and unknown onset seizure types. Underlying mechanisms encompass disrupted excitatory-inhibitory neurotransmitter balance, ion channel dysfunction, synaptic plasticity abnormalities, and network-level hyperexcitability; genetic epilepsies including Dravet syndrome and KCNQ2-related epilepsy represent increasingly recognised and therapeutically relevant molecular entities. Patients present with stereotyped paroxysmal events including convulsions, absence episodes, focal awareness impairment, and automatisms, with diagnosis requiring at least two unprovoked seizures or one seizure with high recurrence risk. Diagnostic workup integrates EEG characterising epileptiform activity and seizure semiology, MRI identifying structural aetiologies, and genetic panel testing in suspected hereditary epilepsies. Antiseizure medications remain the therapeutic cornerstone; levetiracetam, lamotrigine, and valproate are widely utilised first-line agents, with lacosamide, brivaracetam, and cenobamate representing modern options with favourable efficacy and tolerability profiles. Cenobamate has demonstrated particularly compelling seizure freedom rates in focal epilepsy. Cannabidiol is approved for Dravet syndrome and Lennox-Gastaut syndrome. Surgical resection, vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation address drug-resistant epilepsy. Fenfluramine is approved for Dravet syndrome seizure reduction. Prognosis is favourable in two-thirds of patients achieving seizure control; driving restrictions, SUDEP risk counselling, psychosocial support, and patient-centred shared decision-making are integral to comprehensive long-term management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)